Impact of dendritic cells combining with cytokine-induced killer cells synergized chemotherapy in patients of advanced non-small cell lung cancer.
/in Dendritic Cells, NSCLC /von 2013-05-31 / J Clin Oncol 31, 2013 (suppl; abstr e19018)Harnessing the immune system for the treatment of non-small-cell lung cancer
/in International Publications, NSCLC /von 2013-02-11 / J. Clin. Oncol. 2013 Mar;31(8):1021-8Successful treatment of solitary bone metastasis of non-small cell lung cancer with bevacizumab and hyperthermia
/in Hyperthermia, International Publications, NSCLC /von 2012-07-03 / Pathol. Oncol. Res. 2013 Jan;19(1):119-22Immunotherapy of lung adenocarcinoma patient with Peptide-pulsed dendritic cells: a case report
/in Dendritic Cells, International Publications, NSCLC /von 2011-12-06 / Arch. Immunol. Ther. Exp. (Warsz.) 2012 Feb;60(1):69-77Newcastle disease virus induces apoptosis in cisplatin-resistant human lung adenocarcinoma A549 cells in vitro and in vivo
/in International Publications, Newcastle Disease Virus, NSCLC /von 2011-11-15 / Cancer Lett. 2012 Apr;317(1):56-64Mature autologous dendritic cell vaccines in advanced non-small cell lung cancer: a phase I pilot study
/in Dendritic Cells, International Publications, NSCLC /von 2011-06-17 / J. Exp. Clin. Cancer Res. 2011 Jun;30:65Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer
/in Dendritic Cells, International Publications, NSCLC /von 2011-06-17 / Cancer Immunol. Immunother. 2011 Oct;60(10):1497-502Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus
/in International Publications, Newcastle Disease Virus, NSCLC /von 2011-04-06 / Arch. Virol. 2011 Aug;156(8):1335-44Immunotherapy as a strategy for the treatment of non-small-cell lung cancer
/in International Publications, NSCLC /von 2011-01-01 / Therapy 2011 Jan;8(1):43-54
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- From Localized Mild Hyperthermia to Improved Tumor Oxygenation: Physiological Mechanisms Critically Involved in Oncologic Thermo-Radio-Immunotherapy
- Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
- Immunotherapy in breast cancer: an overview of current strategies and perspectives